Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation

Hailong Zhang1 | Xi Chen2 | Beibei Zong1 | Hongmin Yuan3 | Zhizeng Wang1 | Yinxian Wei1 | Xuance Wang4 | Guangchao Liu1 | Jun Zhang1 | Shulian Li1 | Guanchang Cheng5 | Yaohui Wang1 | Yuanfang Ma1

1Joint National Laboratory for Antibody Drug Engineering, Key Laboratory of Cellular and Molecular Immunology of Henan Province, School of Basic Medicine, Henan University, Kaifeng, China
2Department of General Pathology, Huaihe Hospital, Henan University, Kaifeng, China
3Department of Thyroid Breast Surgery, Huaihe Hospital, Henan University, Kaifeng, China
4Centre for Translational Medicine, Huaihe Hospital, Henan University, Kaifeng, China
5Department of Cardiac Surgery, Huaihe Hospital, Henan University, Kaifeng, China

Correspondence
Yaohui Wang and Yuanfang Ma
Emails: wangyaohui2017@henu.edu.cn (YW) and mayf@henu.edu.cn (YM)

Funding information
Natural Science Foundation of Henan Province, Grant/Award Number: 162300410037; National Natural Science Foundation of China, Grant/Award Number: 81670271

Abstract
NLRP3 inflammasome activation plays an important role in diabetic cardiomyopathy (DCM), which may relate to excessive production of reactive oxygen species (ROS). Gypenosides (Gps), the major ingredients of Gynostemma pentaphylla (Thunb.) Makino, have exerted the properties of anti-hyperglycaemia and anti-inflammation, but whether Gps improve myocardial damage and the mechanism remains unclear. Here, we found that high glucose (HG) induced myocardial damage by activating the NLRP3 inflammasome and then promoting IL-1β and IL-18 secretion in H9C2 cells and NRVMs. Meanwhile, HG elevated the production of ROS, which was vital to NLRP3 inflammasome activation. Moreover, the ROS activated the NLRP3 inflammasome mainly by cytochrome c influx into the cytoplasm and binding to NLRP3. Inhibition of ROS and cytochrome c dramatically down-regulated NLRP3 inflammasome activation and improved the cardiomyocyte damage induced by HG, which was also detected in cells treated by Gps. Furthermore, Gps also reduced the levels of the C-reactive proteins (CRPs), IL-1β and IL-18, inhibited NLRP3 inflammasome activation and consequently improved myocardial damage in vivo. These findings provide a mechanism that ROS induced by HG activates the NLRP3 inflammasome by cytochrome c binding to NLRP3 and that Gps may be potential and effective drugs for DCM via the inhibition of ROS-mediated NLRP3 inflammasome activation.

KEYWORDS
cytochrome c, diabetic cardiomyopathy, gypenosides, high glucose, NLRP3 inflammasome, ROS

1 INTRODUCTION

Diabetic cardiomyopathy (DCM) is the primary cause of overt heart failure and death in diabetic individuals and affects nearly 12% of diabetic patients.1-3 Ma et al recently report that the heart failure rate in patients with diabetes is four times that in people without diabetes.4

Strategies regulating blood glucose cannot effectively inhibit the incidence of DCM and improve cardiac dysfunction.5 Moreover, lowering glucose levels could induce adverse cardiovascular outcomes.6 Thus, it is important to seek out the molecular mechanisms that control the progression of DCM and to develop novel methods.

Inflammasomes are cytosolic, multiprotein complexes that are composed of a NOD-like receptor (NLR) or the absent in melanoma (AIM2)-like receptor, ASC and pro-caspase-1.7-9 Among the NLRs,
NLRP3 is best known for sensing the widest array of stimuli, such as nigericin, ATP, ROS, MSU and cholesterol.10–12 When the host receives a signal stimulus, NLRP3 itself can undergo oligomerization, increasing pro-caspase-1 through the adapter protein ASC, which activates caspase-1 and then leads to the cleavage of the interleukin-1β precursor (pro-interleukin-1β) and the interleukin-18 precursor (pro-interleukin-18), causing corresponding inflammation factor IL-1β and IL-18 generation, thus inducing inflammation and necrosis (pyroptosis) and participating in the inflammatory response of cell and tissue.7,13,14

Although the inflammasome plays an important role in the innate immune response and anti-infection immune responses, inflammasome overactivation was shown to be involved in some chronic inflammatory diseases, such as Alzheimer’s, ulcerative colitis, atherosclerosis and type 2 diabetes and its complications.15–19 Hence, inhibiting inflammasome activation may be a promising strategy for DCM. In rats with type 2 diabetes, the NLRP3 inflammasome is up-regulated and promotes the development of DCM.20–22 Inhibiting the activation of the NLRP3 inflammasome can suppress the release of proinflammatory cytokines and attenuate the development of DCM.23,24 In addition, NLRP3 gene silencing alleviates cardiac inflammation and exerts a protective effect on DCM.25 However, the molecular mechanisms by which high glucose (HG) activates the NLRP3 inflammasome in cardiomyocytes remain to be further explored.

As a traditional Chinese medicine, Gynostemma pentaphylla (Thunb.) Makino exerts anti-hypertensive, anti-ageing, anti-hyperlipidemia, anti-hyperglycaemia and anti-inflammation effects.26–30 As a result, Gynostemma has been used to improve symptoms of several diseases for centuries, including hyperlipidemia, hepatitis, atherosclerosis and diabetes. Gypenosides (Gps), the major ingredient of Gynostemma, also possess anti-inflammatory, cardioprotective and neuroprotective properties. In astrocytes and mice stimulated by LPS, Gps suppress NF-κB activation and reduce IL-1β secretion.29 Thus, Gps may inhibit NLRP3 inflammasome activation and improve DCM.

In this study, we utilized HG-stimulated H9C2 and high-fat-diet/STZ-fed rats to study the mechanisms of NLRP3 inflammasome activation. Our study identifies that HG induces mitochondria damage and results in the overproduction of reactive oxygen species (ROS) and the release of cytochrome c, which lead to NLRP3 inflammasome activation and cell death. We further find that ROS activates the NLRP3 inflammasome, which is dependent on cytochrome c in H9C2 treated with HG. Besides these, HG-induced NLRP3 inflammasome activation is inhibited by Gps, which reduces IL-1β release and improves DCM. Consequently, Gps may be a potential therapeutic strategy for DCM.

2 | METHODS

2.1 | Cell culture and treatment

H9C2 cells were purchased from the Library of Typical Culture of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in a DMEM medium supplemented with D-glucose (5.5 mmol/L), 10% FBS, penicillin (100 U/mL) and streptomycin (100 mg/mL). Moreover, neonatal rat ventricular myocytes (NRVMs) were obtained and cultured as previously described.31 In HG-cultured groups, the medium contained 25 or 35 mmol/L of D-glucose. Z-YYAD-FMK, NAC, and cyclosporin A were obtained from Abcam Trading (Shanghai) Company Ltd. Gps were purchased from Yuanye Biology Company (Shanghai) and dissolved in PBS for in vitro and in vivo experiments.

2.2 | Rats

SD rats (7 weeks of age) were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). All animal studies and experiments were permitted by the Animal Experimental Ethics Committee of Henan University. Male rats were bred in a specific pathogen-free facility. After being fed a basal diet for 1 week, rats were randomly divided into chow diet (n = 6) and high-fat diet (n = 30) groups. Four weeks later, 35 mg/kg of streptozotocin (STZ, Solarbio, China) was administered intraperitoneally. One week later, rats fasted for 10 hours and then blood glucose levels were measured by a glucometer (Roche, Germany). The rats whose blood glucose exceeded 12 mmol/L had diabetes and were used for the following study. Then, the diabetic rats were respectively treated with Z-YVAD-FMK (caspase-1 inhibitor, intravenous, 60 mg/kg, n = 6), Gps (intragastric, 200 mg/kg, n = 6), or vehicle (PBS, n = 6) once a day for 8 weeks. Once a week, blood glucose and body weight were detected and recorded. Finally, all rats were killed under anaesthesia. Blood was collected from the carotid artery and centrifuged for 10 minutes at 1800 g at 4°C to obtain the serum. The hearts were rapidly frozen in liquid nitrogen to extract the related genes and proteins or embedded in 4% paraformaldehyde for pathological analysis after lavage.

2.3 | Cell vitality and cell apoptosis

H9C2 cells and NRVMs were maintained with different concentrations of glucose (5.5, 25 and 35 mmol/L), along with Z-YYAD-FMK, NAC, cyclosporin A or Gps. Several hours later (6, 12, 24, 36 and 48 hours), the supernatant of H9C2 cells was obtained to detect cell vitality using LDH. MTS, TUNEL and FCM were used to analyse cell vitality and cell apoptosis, which have been described in previous publications.25,29,32,33

2.4 | Western blot, reverse-transcription and real-time PCR

Western blot (WB) and real-time PCR (RT-PCR) were carried out as previously described.34 Antibodies for NLRP3 and ASC were purchased from Santa Cruz Technology (Santa Cruz, CA). Antibodies for caspase-1, IL-1β, cytochrome c, VDAC, β-actin, GAPDH and the secondary HRP-conjugated antibody were obtained from Cell Signaling Technology (CST). Primers for ASC, NLRP3, caspase-1 and IL-1β genes were obtained from Sangon Biotech Company (Shanghai). The primer sequences are presented in Table S1.
2.5 Immunofluorescence

Immunofluorescence was used to detect the expression of NLRP3 inflammasome markers as previously described. The first antibodies contained anti-NLRP3, ASC, caspase-1 and IL-1β antibodies. An Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody and an Alexa Fluor 594 goat antimouse IgG (H+L) antibody were used as secondary antibodies. Fluorescence was detected with an inverse fluorescent microscope (Nikon, Japan).

2.6 ROS levels

Reactive oxygen species levels were detected with a peroxide-sensitive fluorescent probe 2’, 7’-dichlorofluorescein diacetate (DCFH-DA). After being treated with HG and/or NAC or Gps, H9C2 cells were washed with PBS three times and incubated with DCFH-DA for 30 minutes away from light. The fluorescence was detected with a flow cytometer (BD, America).

2.7 ELISA

Supernatants of the cell culture or serum were used to measure IL-1β, IL-18 and C-reactive protein (CRP) (Thermo Fisher Scientific) according to the manufacturer’s instructions.

2.8 Histological examination

After the rats were killed, their hearts were perfused with PBS and bisected at the mid-ventricular level. Then, the hearts were fixed in 4% paraformaldehyde and embedded in paraffin. Four micrometre sections were stained with haematoxylin and eosin (H&E), and images were randomly captured by microscope.

2.9 Co-immunoprecipitation

Co-immunoprecipitation (CoIP) was carried out as previously described. 1 mg of cell lysate was treated with protein A/G agarose beads for 1 hour. After being centrifuged for 10 minutes, the supernatants were incubated with an anti-NLRP3 antibody overnight at 4°C. Then, 100 µL protein A/G agarose beads were added to the supernatants and mixed for 2 hours. The beads were centrifuged and washed five times with a lysis buffer. The samples were subjected to immunoblotting with the anti-cytochrome c antibody and corresponding secondary antibodies.

2.10 Statistical analysis

All data were shown as mean ± SD. Samples were analysed using a one-way ANOVA on SPSS 16.0 software. P < .05 was considered a statistically significant difference.

3 RESULTS

3.1 HG-induced cell injury in cardiomyocytes

To investigate the effect of HG on H9C2 cells, the cells were treated with different concentrations of glucose for 6, 12, 24, 36 and 48 hours. The supernatants were measured using commercial LDH kits, while the residual cells were used for an MTS assay. Although 25 and 35 mmol/L of glucose could induce H9C2 to release more LDH than 5.5 mmol/L of glucose, there are no statistical differences within a short period of time (6 and 12 hours) (Figure 1A). After the H9C2 cells were treated at 24, 36 and 48 hours, we found that HG dramatically resulted in cell damage in a dose-dependent manner (Figure 1A). The MTS assay also showed that HG reduced myocardial viability in the same manner (Figure 1B). In addition to the H9C2 cells, NRVMs treated with HG simultaneously showed cell damage (Figure S1A,B). Meanwhile, HG signally induced H9C2 cell apoptosis, and this effect was dose-dependent (Figure 1C-E). Cell apoptosis in response to HG was confirmed using NRVMs (Figure S1C,D).

To examine whether osmotic pressure affected cardiomyocyte viability, the H9C2 cells were treated with equal concentrations of mannitol. We found that the cell damage and activity were not significantly changed, which suggested that the cell injury depended on glucose itself, not osmotic pressure (Figure 1A,B).

3.2 High glucose-induced cardiomyocyte injury mainly depended on NLRP3 inflammasome activation

To determine the role of NLRP3 inflammasome activation on HG-induced cardiomyocyte injury, NLRP3 inflammasome activation in H9C2 and NRVMs was first assessed. HG facilitated the expression of NLRP3, ASC, caspase-1 and IL-1β genes, and this effect was dose- and time-dependent in H9C2 cells and NRVMs (Figures 2A-D and S2A-D). We next investigated IL-1β secretion in H9C2 and NRVMs stimulated with HG through ELISA, which relied on NLRP3 inflammasome activation. As shown in Figures 2E and S2E, HG remarkably stimulated IL-1β secretion. Meanwhile, the level of IL-1β, another NLRP3 inflammasome-dependent cytokine, was also signally elevated in NRVMs (Figure S2F).

Moreover, an immunoblotting assay also revealed that NLRP3 and ASC protein levels were elevated in H9C2 cells and NRVMs treated with HG (Figures 2F-H and S2G), while pro-caspase-1 and pro-IL-1β protein levels had not changed (Figures 2F,I,J and S2G). Consistent with the ELISA results, HG induced mature IL-1β production in cell supernatants (Figures 2F,K and S2G). Furthermore, caspase-1 P20 levels were increased in supernatants of H9C2 and NRVMs stimulated with HG (Figures 2F,L and S2G). Besides these results, HG promoted the expressions of NLRP3, ASC, total caspase-1 and IL-1β proteins performed with immunofluorescence (Figure S3).

To determine whether HG-induced NLRP3 inflammasome activation is responsible for cardiomyocyte injury, the effects of HG on NLRP3 inflammasome activation and cardiocyte injury were assessed after NLRP3 was silenced in H9C2 cells. As shown in Figure 3A, the level of
NLRP3 protein was obviously reduced in H9C2 cells treated with siRNA, even under a HG condition. Meanwhile, NLRP3 deficiency blocked HG-induced NLRP3 inflammasome activation, caspase-1 p20 production and mature IL-1β secretion (Figure 3B). Additionally, an ELISA assay for IL-1β in supernatants showed that IL-1β diminished in the absence of NLRP3 (Figure 3C). Most of all, the cell injury induced by HG improved when NLRP3 was silenced (Figure 3D,E). Correspondingly, the effects of HG on NLRP3 inflammasome activation and cardiocyte injury were confirmed using the caspase inhibitor Z-YVAD-FMK (Figure 3F-I). Thus, these data indicated that HG-induced NLRP3 inflammasome activation was responsible for H9C2 cell injury.

3.3 High glucose-induced ROS release accounted for NLRP3 inflammasome activation

To ascertain the mechanisms of NLRP3 inflammasome activation, we examined ROS release, a common stimulator associated with inflammasome activation. In agreement with previous reports, stimulation was done with HG-induced cytochrome c influx into cytoplasm, which meant the mitochondrion was damaged (Figure 4A). Correspondingly, HG promoted ROS generation, and this increase was dose-dependent manner. Additionally, the level of NLRP3 was lower in groups treated with NAC than in the control group (Figure 4D). The expressions of mIL-1β and cleaved caspase-1 (P20) were also downregulated in NAC-treated groups than in the DMSO-treated group (Figure 4D). The cell damage and viability of H9C2 were obviously improved with the pretreatment of NAC compared with DMSO (Figure 4E,F). Thus, these data indicate that ROS release accounted for NLRP3 inflammasome activation induced by HG.

3.4 Cytochrome c mediated the ROS-induced NLRP3 inflammasome activation

Although emerging data showed that ROS can induce NLRP3 inflammasome activation, the exact mechanisms were still uncertain. We next found that NAC not only inhibited ROS release, but also improved cytochrome c influx into cytoplasm (Figure 5A). To identify whether cytochrome c regulated NLRP3 inflammasome activation, cyclosporine A was used to stimulate H9C2 cells along with HG. Cyclosporine A, as an inhibitor of cytochrome c, could effectively inhibit cytochrome c influx into cytoplasm, which was also proved by our data (Figure 5B). Furthermore, cyclosporine A could inhibit the expression of NLRP3, which was increased by HG (Figure 5C). The protein levels of mIL-1β and P20 were also reduced by cyclosporine A (Figure 5D). The cell damage and viability of H9C2 were obviously improved with the pretreatment of cyclosporine A compared with DMSO (Figure 5D,E).
To detect the mechanisms by which cytochrome c activated NLRP3 inflammasome, CoIP was used. The data showed that cytochrome c could bind to NLRP3, even in the presence of cyclosporine A (Figure 5F). Collectively, these data indicated that cytochrome c could bind to NLRP3, which mediated the ROS-induced NLRP3 inflammasome activation.

### 3.5 Gps improved HG-induced cardiomyocyte damage

To investigate the effect of Gps on HG-induced cardiomyocyte injury, H9C2 cells were treated with Gps for 48 hours along with 35 mmol/L glucose. We found that Gps noticeably inhibited LDH release and improved cell viability in a dose-dependent manner (Figure 6A,B). Alternatively, cardiomyocyte injury could be confirmed by cell apoptosis via FCM. In agreement with Figure 6A,B, HG-induced cell apoptosis was dose-dependently inhibited by Gps (Figure 6C). The mean percent of apoptosis cells was 17.18% in the HG-treated group, compared to 5.46%, 5.88% and 5.41% in several concentrations of the Gps-treated groups (Figure 6D).

### 3.6 Gps suppressed NLRP3 inflammasome activation by inhibiting ROS release

To determine whether Gps’s improvement of cardiomyocyte injury relied on regulating NLRP3 inflammasome activation, the effects of Gps on NLRP3 inflammasome activation were assessed. Gps dramatically inhibited the secretion of IL-1β and cleaved caspase-1 (p20), which were induced by 35 mmol/L of glucose (Figure 7A). Meanwhile, the production of NLRP3 was also dose-dependently inhibited by Gps (Figure 7A). Corresponding to the immunoblotting results, the levels of IL-1β and IL-18 proteins in medium supernatants of H9C2 cells were dramatically reduced by Gps (Figure S4A,C). However, in H9C2 cells treated with 5.5 mmol/L of glucose, Gps did not influence the production of NLRP3 and ASC (Figure S4A-C). The secretion of IL-1β and p20 had also not changed (Figure S4A,D and E). Meanwhile, the ELISA results showed that Gps made no difference in the secretion of IL-1β and IL-18 (Figure S4F,G).

To determine the mechanisms by which Gps inhibited NLRP3 inflammasome activation, we next examined ROS release. As shown in Figures 4B and 7D, stimulation with HG-induced ROS release in
H9C2 cells. Moreover, this effect could be effectively inhibited by Gps in a dose-dependent manner (Figure 7D,E).

Next, we examined the impact of Gps on cytochrome c influx into cytoplasm. Consistent with the ROS release, Gps (400 mg/L) dramatically inhibited cytochrome c influx into cytoplasm, which was induced by HG (Figure 7F). Collectively, the above data indicate that Gps inhibited ROS release and cytochrome c influx into cytoplasm, and then regulated NLRP3 inflammasome activation.

### 3.7 | In vivo, gypenosides prevented NLRP3 inflammasome activation and attenuated HG-induced myocardial injury

We next investigated the effects of Gps in vivo. Mice fed with HFD were treated with Gps or Z-YVAD-FMK 1 week after i.p. administration of STZ and were monitored for 8 weeks. Corresponding to other research, Gps significantly reduced blood glucose and improved

![Figure 3](image3.png) Silencing NLRP3 or inhibiting caspase-1 suppressed NLRP3 inflammasome activation and improved cardiomyocyte damage. A. The level of NLRP3 protein in H9C2 cells treated with DR5-targeted siRNA was analysed by immunoblotting as indicated in the text. B, Silencing NLRP3 inhibited caspase-1 activation and IL-1β secretion in the medium supernatants (Sup) and cell lysates (Lys) of H9C2 cells. C, Supernatants of H9C2 cells treated with DR5-targeted siRNA were analysed by ELISA for IL-1β. D-E, LDH (D) and MTS (E) were used to detect cell damage in H9C2 cells treated with siRNA. F, The levels of NLRP3 inflammasome markers were assayed via immunoblotting in H9C2 cells treated with Z-YVAD-FMK (YVAD) for 48 h. G, Supernatants of H9C2 cells were also analysed by ELISA for IL-1β. H-I, LDH (H) and MTS (I) were used to detect cell damage in H9C2 cells treated with Z-YVAD-FMK (YVAD). Data are shown as mean ± SD. *P ≤ .05, **P ≤ .01, ***P ≤ .001

![Figure 4](image4.png) Inhibiting ROS-suppressed NLRP3 inflammasome activation and improved cardiomyocyte damage. A. The cytoplasm and mitochondrion of H9C2 cells were analysed by immunoblotting for cytochrome c after treating with high glucose for 48 h. B, ROS release was detected by FCM in H9C2 cells treated with high glucose for 48 h. C, ROS release was detected by FCM in H9C2 cells treated with high glucose and/or NAC for 48 h. D, The levels of NLRP3 inflammasome markers were assayed via immunoblotting in H9C2 cells treated with NAC for 48 h. E-F, LDH (E) and MTS (F) were used to detect cell damage in H9C2 cells treated with NAC. Data are shown as mean ± SD. *P ≤ .05, **P ≤ .01
the loss of body weight, whereas Z-YVAD-FMK had no obvious effects on blood glucose and body weight (Figure 8A,B). Compared to normal mice, mice fed with HFD and then administered with STZ obviously had myocardial injury, whereas the caspase-1 inhibitor (Z-YVAD-FMK) and Gps significantly alleviated the induction and injury by HFD (Figure 8C). As an important marker of activation, the level of CRP was markedly higher in mice treated with HFD and STZ than in normal mice. Z-YVAD-FMK and Gps significantly reduced CRP production (Figure 8D). These data suggest that Gps attenuated disease development by reducing blood glucose and inhibiting inflammatory activation in vivo.

To evaluate the role of Gps on NLRP3 inflammasome activation in vivo, the total heart protein in these groups was used to detect NLRP3 inflammasome activation. The levels of NLRP3 and ASC were significantly higher in mice treated with HFD and STZ than in normal mice. Z-YVAD-FMK and Gps significantly reduced NLRP3 inflammasome activation (Figure 8E). These data suggest that Gps attenuated disease development by reducing blood glucose and inhibiting inflammatory activation in vivo.

FIGURE 5 Cytochrome c mediated the ROS-induced NLRP3 inflammasome activation. A, The cytoplasm and mitochondrion of H9C2 cells were analysed by immunoblotting for cytochrome c after treating with high glucose and/or NAC for 48 h. B, The cytoplasm and mitochondrion of H9C2 cells were analysed by immunoblotting for cytochrome c after being treated with high glucose and/or cyclosporin A for 48 h. C, The levels of NLRP3 inflammasome markers were assayed via immunoblotting in H9C2 cells treated with high glucose and/or cyclosporin A for 48 h. D-E, LDH (D) and MTS (E) were used to detect cell damage in H9C2 cells treated with cyclosporin A. F, H9C2 cell lysates were analysed by CoIP for NLRP3 and cytochrome c as indicated in the text. Data are shown as mean ± SD. *P ≤ .05, **P ≤ .01.
FIGURE 6  Gps improved cardiomyocyte damage. A-B, LDH (A) and MTS (B) assays were detected in H9C2 cells treated with Gps for 48 h. C-D, Representative images of FCM of H9C2 cells treated with Gps for 48 h (C) and the statistical result of apoptosis cells (D). Data are shown as mean ± SD. *P ≤ .05, **P ≤ .01, ***P ≤ .001.

FIGURE 7  Gps suppressed NLRP3 inflammasome activation by inhibiting ROS release. A, The levels of NLRP3 inflammasome markers were assayed via immunoblotting in the medium supernatants (Sup) and lysates (Lys) of H9C2 cells treated with Gps for 48 h. B-C, The levels of IL-1β (B) and IL-18 (C) proteins in medium supernatants of H9C2 cells were analysed by ELISA after being treated with Gps for 48 h. D-E, ROS release was detected by FCM in H9C2 cells treated with Gps for 48 h (D) and the statistical result of positive cells (E). F, The cytoplasm and mitochondrion of H9C2 cells were analysed by immunoblotting for cytochrome c after treating with Gps for 48 h. Data are shown as mean ± SD. **P ≤ .01, ***P ≤ .001.
innate immune cells are important hallmarks of DCM.\textsuperscript{14,18,24} The levels of CCL2, IL-1\textbeta and other proinflammatory cytokines are dramatically reduced in NLRP3-deficient mice.\textsuperscript{38} Moreover, inhibiting NLRP3 activation or NLRP3 gene silencing exerts a protective role on DCM.\textsuperscript{25,39} Interestingly, some researchers declare that NLRP3 inflammasome activation and subsequent IL-1\textbeta secretion in the heart mainly exist in fibroblasts, endothelial cells and leukocytes, while cardiomyocytes cannot secrete IL-1\textbeta. However, there is considerable evidence that NLRP3 inflammasome activation and IL-1\textbeta secretion induced by HG exist in cardiomyocytes and cause myocardial damage, including in our results.\textsuperscript{14,39,40} In this study, we also found that HG significantly induced NLRP3 inflammasome formation and

---

**FIGURE 8** Gps inhibited NLRP3 inflammasome activation and DCM development in vivo. A-B, Blood glucose (A) and body weight (B) were measured every week for 13 wk after HFD administration. C, Myocardial tissue sections were stained with H&E fluid to detect myocardial injury. D, The level of CRP protein in the serum was analysed by ELISA. E, The levels of NLRP3 inflammasome markers were assayed via immunoblotting in myocardial tissue. F-G, The levels of IL-1\textbeta (F) and IL-18 (G) proteins in serum were analysed by ELISA. H-K, The gene levels of NLRP3 (H), ASC (H), caspase-1 (G) and IL-1\textbeta (K) were assayed via RT-PCR in myocardial tissue. Data are shown as mean ± SD. *P ≤ .05, **P ≤ .01, ***P ≤ .001.
activation and led to the enhanced production of mature IL-1β and IL-18 in H9C2 cells and NRVMs. Meanwhile, NLRP3 gene silencing and/or the caspase-1 inhibitor (Z-YVAD-FMK) dramatically weakened NLRP3 inflammasome activation and the expression of mature IL-1β not only in H9C2 cells, but also in NRVMs. In vivo, the NLRP3 inflammasome activation was observed in the heart of T2D mice accompanied by DCM. Meanwhile, we found that the level of IL-1β in serum was dramatically elevated. Interestingly, as one caspase inhibitor, Z-YVAD-FMK could not obviously improve the blood glucose and body weight in the mice sustained DCM. However, Z-YVAD-FMK could suppressed the activation of caspase 1 and the production of IL-1β, and had a negative effect on the expression NLRP3 and ASC, which improved the myocardial damage.

Although these data show a close relationship between HG-induced myocardial damage and NLRP3 inflammasome activation, the mechanism by which HG activates NLRP3 inflammasome is still not clear. Recent studies suggest that mitochondrial ROS is required for NLRP3 inflammasome activation.\(^{41-43}\) Moreover, many studies have indicated that mitochondrial damage and oxidative stress are important risk factors for DCM and that mitochondrial ROS is a pivotal link between oxidative stress and NLRP3 inflammasome activation.\(^{44,45}\) Recently, a study has shown that monocytes and/or MDMs from T2D or DCM patients stimulated with DAMP release an elevated level of ROS.\(^{18}\) Meanwhile, ROS inhibitors dramatically inhibit the secretion of mature IL-1β and IL-18. Consistent with these data, we found that H9C2 cells stimulated by HG produced elevated levels of ROS, which induced NLRP3 inflammasome activation and subsequent myocardial damage. NAC, a kind of ROS inhibitor, dramatically inhibited NLRP3 inflammasome activation and decreased the secretion of mature IL-1β.

The NLRP3 inflammasome activation contains two steps.\(^{7,46}\) In the first step, which is also called the priming step, PAMP recognizes pathogen response receptors (PRRs) and then activates NF-κB, which leads to increased levels of NLRP3, IL-1β and IL-18 genes and proteins. In the second step, many stimuli (uric acid, cardiolipin, dsDNA and so on) induce the formation of the NLRP3 inflammasome and subsequently activate it to produce mature IL-1β and IL-18. Initially, ROS were supposed to be one key stimulator participating in the priming step of NLRP3 inflammasome activation, because they were required for NK-κB activation.\(^{47}\) Indeed, we found that the inhibition of ROS by NAC could reduce the production of NLRP3 protein and mature IL-1β, while the levels of NLRP3, caspase-1 and IL-1β did not obviously change (data not shown). This means that ROS may be crucial to the second step of NLRP3 inflammasome activation.

However, the mechanism by which ROS activate the NLRP3 inflammasome is still unclear. Some studies find that ROS can dissociate the thioredoxin-interacting protein (TXNIP) from the TXNIP-TXN complex, and free TXNIP induces NLRP3 inflammasome formation and activation.\(^{46,48}\) Inhibiting TXNIP can effectively down-regulate NLRP3 inflammasome activation and IL-1β secretion.\(^{44}\) Moreover, one study has recently shown that ROS can directly induce the formation of the caspase-1-ASC complex and activate the NLRP3 inflammasome.\(^{45}\) In the current study, we found that ROS could induce cytochrome c influx into cytoplasm, which directly bound to NLRP3 and led to NLRP3 inflammasome activation. Cyclosporin A (a cytochrome c inhibitor) could significantly inhibit NLRP3 inflammasome activation and mature IL-1β secretion, while the ROS level was not influenced. Even so, the mechanisms by which ROS regulate cytochrome c influx into cytoplasm and cytochrome c activates NLRP3 inflammasome deserve further research.

Gps, the major component of Gynostemma pentaphylla (Thunb.) Makino, have shown the properties of hypoglycaemic action and anti-inflammation. In the current study, we found that Gps can inhibit NLRP3 inflammasome activation and IL-1β and IL-18 secretion, which might result from their ability to reduce the level of mitochondrial ROS. In vivo, Gps could reduce the level of blood glucose, inhibit the expression of NLRP3 protein and IL-1β production and improve myocardial damage. Meanwhile, the generic levels were also reduced in mice administrated with Gps, which suggested that Gps might regulate the priming step of the NLRP3 inflammasome.

In summary, our data demonstrated that Gps inhibited HG-induced myocardial damage through the ROS-induced NLRP3 inflammasome activation in vitro and in vivo. Meanwhile, the ROS-activated NLRP3 inflammasome might result from cytochrome c binding to NLRP3. Therefore, Gps may be a potential therapeutic solution for inhibiting NLRP3 inflammasome activation and NLRP3-associated syndromes.

**ACKNOWLEDGEMENTS**

This work was supported by the National Natural Science Foundation of China (No. 81670271) and Henan Provincial Natural Science Foundation (No. 162300410037).

**CONFLICT OF INTEREST**

The authors declare no conflict of interests.

**ORCID**

Hailong Zhang http://orcid.org/0000-0003-3316-4290

**REFERENCES**

1. Wei H, Qu H, Wang H, et al. 1,25-Dihydroxyvitamin-D3 prevents the development of diabetic cardiomyopathy in type 1 diabetic rats by enhancing autophagy via inhibiting the beta-catenin/TCF4/GSK-3beta/mTOR pathway. J Steroid Biochem Mol Biol. 2017;168: 71-90.

2. Liu W, Ruiz-Velasco A, Wang S, et al. Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nat Commun. 2017;8:494.

3. Lorenzo-Almoros A, Tunon J, Orejas M, Cortes M, Egido J, Lorenzo O. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16:28.

4. Ma ZG, Yuan YP, Xu SC, et al. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. Diabetologia. 2017;60:1126-1137.
5. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142:375-415.

6. Udelli JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3:356-366.

7. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-687.

8. Gurung P, Li B, Subbarao Malireddi RK, Lamkanfi M, Geiger TL, Kannegati TD. Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation. Sci Rep. 2015;5:14488.

9. Tang T, Lang X, Xu C, et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Acta Pharmacol Sin. 2017;8:202.

10. Rajanbabu V, Galam L, Fukumoto J, et al. Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2. Cell Immunol. 2015;297:40-45.

11. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol. 2011;187:613-617.

12. Gaide O, Hoffman HM. Insight into the inflammasome and caspase-activating mechanisms. Expert Rev Clin Immunol. 2008;4:61-77.

13. Kim JK, Jin HS, Suh HW, Jo EK. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling. Immunol Cell Biol. 2017;95:584-592.

14. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148-159.

15. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857-865.

16. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379-391.

17. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.

18. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194-204.

19. Wang C, Pan Y, Zhang QY, Wang FM, Kong LD. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS ONE. 2012;7:e38285.

20. Luo B, Li B, Wang W, et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther. 2014;28:33-43.

21. Fuentes-Antras J, Ioan AM, Tunon J, Egidio J, Lorenzo O. Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. Int J Endocrinol. 2014;2014:847827.

22. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118:1808-1829.

23. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum YA. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119-132.

24. Huang Z, Zhuang X, Xie C, et al. Exogenous hydrogen sulfide attenuates high glucose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation by suppressing TLR4/NF-kappaB pathway in H9c2 cells. Cell Physiol Biochem. 2016;40:1578-1590.

25. Luo B, Li B, Wang W, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE. 2014;9:e104771.

26. Zhang HK, Ye Y, Zhao ZN, et al. Neuroprotective effects of gypenosides in experimental autoimmune optic neuritis. Int J Ophthalmol. 2017;10:541-549.

27. Zhao TT, Kim KS, Shin KS, et al. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson’s disease treated with E755. BMC Complement Altern Med. 2017;17:449.

28. Shin KS, Zhao TT, Choi HS, Hwang BY, Lee CK, Lee MK. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson’s disease. Brain Res. 2014;1567:57-65.

29. Wang X, Yang L, Yang L, et al. Gypenoside IX suppresses p38 MAPK/Akt/NF-kappaB signaling pathway activation and inflammatory responses in astrocytes stimulated by proinflammatory mediators. Inflammation. 2017;40:2137-2150.

30. Quan Y, Yang Y, Wang H, Shu D, Zhang QH, Qian M. Gypenosides attenuate cholesterol-induced DNA damage by inhibiting the production of reactive oxygen species in human umbilical vein endothelial cells. Mol Med Rep. 2015;11:2945-2951.

31. Louch WE, Sheehan KA, Wolska BM. Methods in cardiomyocyte isolation, culture, and gene transfer. J Mol Cell Cardiol. 2011;51:288-298.

32. Yu SX, Du CT, Chen W, et al. Genipin inhibits NLRP3 and NLR4 inflammasome activation via autopagy suppression. Sci Rep. 2015;5:17935.

33. Zhou T, Liang Y, Jiang L, Yu T, Zeng C, Tao E. Mild hypothermia protects against oxygen glucose deprivation/reoxygenation-induced apoptosis via the Wnt/beta-catenin signaling pathway in hippocampal neurons. Biochem Biophys Res Commun. 2017;486:1005-1013.

34. Bryson TD, Gu X, Khalil RM, et al. Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction. J Mol Cell Cardiol. 2018;118:1-12.

35. Dong Z, An F, Wu T, et al. PTX3, a key component of innate immunity, is induced by SAA via FPR1-mediated signaling in HAECs. J Cell Biochem. 2011;112:2097-2105.

36. Cui X, Xie PP, Jia PP, et al. Hsf4 counteracts Hsf1 transcription activities and increases lens epithelial cell survival in vitro. Biochim Biophys Acta. 2015;1853:746-755.

37. Dror E, Dalmas E, Meier DT, et al. Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017;18:283-292.

38. VandanaSingh B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188.

39. Wen H, Ting JP, O’Neill LA. A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? Nat Immunol. 2012;13:352-357.

40. Bracey NA, Beck PL, Muruve DA, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol. 2013;98:462-472.

41. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222-230.

42. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab. 2011;301:E749-E755.

43. Masters SL, Latz E, O’Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med 2011;3:81ps17.
44. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. *Nat Rev Drug Discov*. 2011;10:453-471.

45. Zhang X, Fu Y, Li H, et al. H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose. *J Cell Mol Med*. 2018;22:1816-1825.

46. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. *Nat Rev Cardiol*. 2017;15:203-214.

47. Hornung V, Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. *Eur J Immunol*. 2010;40:620-623.

48. Liu Y, Lian K, Zhang L, et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. *Basic Res Cardiol*. 2014;109:415.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Zhang H, Chen X, Zong B, et al. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. *J Cell Mol Med*. 2018;22:4437–4448. [https://doi.org/10.1111/jcmm.13743](https://doi.org/10.1111/jcmm.13743)